reports
ORYZON Strengthens Patent Portfolio for iadademstat with European Gran...
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application EP20712594.9, entitled “Combinations of iadademstat for cancer therapy”. The allowed claims protect the use of iadademstat in combination with PD1 or P...
ORYZON to Participate in Upcoming Events in September and October
ORYZON to Participate in Upcoming Events in September and October MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the following upcoming events: Drug Discovery Innovation Programme, September 25-26Location: Intercontinental Hotel, Barcelona, Spain Paris Midcap Event 2025, September 30-October 1Location: Four Seasons George V, Paris, France BME Investor Access Event 2025, October 7Lo...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat wi...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant In Australia and Europe MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it continues to expand its patent portfolio for iadademstat and vafidemstat, Oryzon’s clinical-stage LSD1 inhibitors for oncology and central nervous system (CNS) disorders, following new Decisions to Grant from the Australian and European patent office...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Finalist at the 2025 European Lifestars Awards
ORYZON Finalist at the 2025 European Lifestars Awards In the Category Post-IPO Raise of the Year MADRID, Spain and CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has been selected as a Finalist in the 2025 European Lifestars Awards in the category Post-IPO Raise of the Year for the European Mediterranean region. The Lifestars Awards bring together leading figures from across the European life sciences industry, in...
ORYZON Receives European Medicines Agency Approval to Initiate a Phase...
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND, to initiate a Phase Ib trial of iadademstat in ...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Reports Financial Results and Corporate Update for Half-Year En...
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025 Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1.8 M from R&D cash-back incentives)Company has terminated the Convertible Bonds financing facility with Nice&GreenClinical trial protocol for vafidemstat’s Phase III PORTICO-2 trial in BPD submitted to the FDAExpansion of ongoing Phase IIb EVOLUTION study with vafidemstat in schizophrenia into other EU coun...
Expanding Analyst Interest in ORYZON
Expanding Analyst Interest in ORYZON New U.S. investment bank joins, bringing total coverage to ten analysts MADRID and CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that Maxim LLC, a U.S.-based investment bank, has initiated research coverage of the company, effective July 18, 2025. This milestone reflects Oryzon’s ongoing commitment to transparency and proactive communication with the investment community. Over the years,...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat New “Decision to grant” communications in Canada and Israel For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804 and IL272092, titled “Meth...
ORYZON to Host Virtual KOL Event on July 9, 2025
ORYZON to Host Virtual KOL Event on July 9, 2025 To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial in BPD MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on Wednesday, July 9, 2025 at 12:00 pm ET. The event, moderated by Michael Ropacki, PhD and Oryzon’s CMO for CNS, will feature insights from leading exp...
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate P...
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patientsPrimary endpoint: STAXI-2 Trait Anger (patient-reported)Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) (clinician-rated)Additional secondary endpoints will assess global clinical improvementProtocol finalized following FDA guidance and input from leading US psychiatry expertsUpcoming KOL webinar to discuss trial design and the urgent me...
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in B...
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29 Oryzon’s CSO, Dr. Jordi Xaus, will participate in a Panel entitled “Industry Perspectives Discussion” on June 2770-90% of PMS patients show autistic related features, including aggressionAgitation/Aggression in PMS and other ASD-related patient subpopulations are the main focus of Oryzon’s VANDAM project included in the Med4Cure IPCEI projectOryzon is glad to participate as Sponsor of the congress MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0...
ORYZON to Provide Corporate Progress Updates at Several Events in May-...
ORYZON to Provide Corporate Progress Updates at Several Events in May-June Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will give an update on corporate progress at several international events in May-June. Oryzon will attend the Foro Medcap 2025, which will take place at the Madrid Stock Exchange palace in Madrid (...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Reports Financial Results and Corporate Update for Quarter Ende...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025 Successful completion of €30 Million capital increase, with strong international demand and oversubscriptionAwarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)Vafidemstat’s Phase III PORTICO-2 trial endpoints for agitation and aggression in BPD defined with input from new Clinical Advisory Board; finalizing preparations for Phase III Results of observational clinical study on Phelan-McDermid syndr...
ORYZON Awarded €13.26 Million Through the First Important Project of C...
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project) Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision medicine clinical scope of vafidemstatOryzon will also explore the targeted activity of iadademstat in several difficult-to-treat neuroendocrine cancersFunding covers 64% of Oryzon’s VANDAM project total budg...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
ORYZON Raises €30 Million in Capital Increase
ORYZON Raises €30 Million in Capital Increase Issued 12,765,958 new sharesPriced at €2.35 per share, representing a 15.44% discount on the 5-day VWAPStrong investor demand, with the offering significantly oversubscribed€15 million anchored by a leading US institutional investorProceeds to fund clinical development and corporate initiatives MADRID and CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion of a €3...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.